Listen
Watch
Lung cancer has shown a decrease in incidence and mortality in recent decades; however, it remains one of the cancers with the highest incidence and still ranks first in cancer-related deaths in the United States. Advancements like molecular interpretation of lung cancer has substantially changed the classification and treatment of these tumors, becoming an essential component of pathologic diagnosis and oncologic therapy decisions. Through the recognition of novel biomarkers, such as epidermal growth factor receptor mutations and anaplastic lymphoma kinase translocations, it has been possible to identify subsets of patients who benefit from targeted molecular therapies.
We’re encouraging patients to learn more about their lung health by offering special pricing on lung screenings through the month of November. Patients without health insurance or whose insurance does not cover the test can receive a lung screening for $35. A prescription is required. This Lung Cancer Awareness Month, stay on top of your lung health by visiting BaptistHealth.net/LungScreening or call 833-596-2473.
Related Presenters
Manmeet Ahluwalia, M.D., MBA, FASCO
Chief of Medical Oncology, Chief Scientific Officer & Deputy Director, Fernandez Family Endowed Chair in Cancer Research Baptist Health Miami Cancer Institute
Manmeet Ahluwalia, M.D., MBA, FASCO, is the chief scientific officer, chief of medical oncology, deputy director and Fernandez Family Endowed Chair in Cancer Research at Baptist Health Miami Cancer Institute.
Executive Director of LUNGevity ResearcTop of Formh